TissueLabs is a technology company.
TissueLabs has raised $800K across 1 funding round.
TissueLabs has raised $800K in total across 1 funding round.
TissueLabs has raised $800K in total across 1 funding round.
TissueLabs's investors include Breega, Lupa Capital, Oak HC/FT, Hugo Arevalo, Humberto Ayres Pereira, Job Van Der Voort, Mats Diedrichsen.
TissueLabs is a Swiss biotech company founded in 2019, specializing in biofabrication platforms that enable the creation of complex 3D tissues and organs in the lab through advanced 3D bioprinting systems and tissue-specific biomaterials.[1][2][3] It serves academic researchers, pharmaceutical companies, and research institutions by providing tools like the TissueStart™ and TissueRay™ bioprinters, MatriXpec™ hydrogels, and MatriSponge™ scaffolds, addressing challenges in drug discovery, reducing animal testing, and advancing regenerative medicine toward transplantable organs such as a bioartificial heart.[3][5][6] The company demonstrates strong growth momentum, with its technology adopted by thousands of scientists in hundreds of institutions across over 30 countries, and recent expansions into applications like bioprinted human heart models for cardiac safety studies.[6]
TissueLabs was founded in 2019 in Manno (with operations in Bellinzona), Switzerland, emerging from a mission to produce human organs for transplantation and revolutionize tissue engineering.[2][3][7] While specific founders are not detailed in available sources, the team comprises experts in biofabrication, biomaterials, tissue engineering, biotech innovation, and product development, drawn from premier global institutions.[3][7] The idea stemmed from integrating cutting-edge 3D bioprinting with specialized biomaterials to create functional tissues, gaining early traction through an open platform that fosters global research community input and positions the company as a pioneer in Swiss biotech.[1][3] Pivotal moments include participation in accelerators, awards like Prix Strategis semi-finalists in 2023, and international expansions such as business voyages to Boston in 2024.[4]
TissueLabs rides the wave of regenerative medicine and biofabrication, capitalizing on trends like 3D bioprinting for human-relevant tissue models amid rising demand for alternatives to animal testing and solutions to organ shortages.[1][3][6] Timing is ideal with regulatory shifts favoring ethical, data-rich preclinical tools and industry pushes for personalized medicine, positioning it against competitors like CELLINK and Organovo in a market growing via pharma collaborations.[2][6] Market forces such as Switzerland's strong biotech ecosystem, funding for deep-tech startups, and global needs for transplantable organs (e.g., hearts) favor its growth, while it influences the ecosystem by empowering thousands of researchers, fostering pharma-hospital connections, and advancing toward implantable tissues.[3][4][6]
TissueLabs is poised to scale its platform toward clinical translation, with next steps including bioprinted heart models for drug safety, regulatory advancements, and commercial expansion via strengthened clinical and sales teams.[3][6] Trends like AI-enhanced bioprinting, increased deep-tech funding, and global regulatory harmonization for advanced therapies will shape its path, potentially evolving its influence from research enabler to leader in transplantable organs. This builds on its core mission—transforming lab-grown tissues into life-saving realities—driving the next era of healthcare innovation.[7]
TissueLabs has raised $800K across 1 funding round. Most recently, it raised $800K Seed in September 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2023 | $800K Seed | Breega, Lupa Capital, Oak HC/FT, Hugo Arevalo, Humberto Ayres Pereira, Job Van Der Voort, Mats Diedrichsen |